By: Tanner Logsdon
May 8, 2017
A Finnish study from ELSEVIER sponsored by Orium, is reporting a possible breakthrough in the field of Alzheimer’s treatment. The new drug called, ORM-12741 is a treatment drug not meant to cure the disease but rather halt the process and give the patients dealing with moderate Alzheimer’s relief and more time.
Alzheimer’s is a disease that affects cognitive memory and brain functions. The disease slowly deteriorates the brain and can eventually lead to death after the seventh stage. With this being said there is little that medicine or other treatments can do and the disease does not have a cure. ORM for short, is a drug developed to slow the process by targeting alpha-2C adrenoceptors in the brain, which are responsible for initiating the “fight or flight” response in our nervous system in reactions to tress related environments. This drug is the first of its kind to target specific receptors in the brain such as alpha-2C’s and is already showing process in its trial runs.
During the study there were 2 main targets, safety and results, both of which showed promise. The test involved a total of 100 people who had a mild-moderate case of Alzheimer’s. Out of those 100 patients 50 received a placebo drug acting as a dummy drug and their results showed a 33 percent decrease in cognitive memory, while the other 50 patients were given either a low-dose (30 to 60 milligrams) twice daily supply of ORM-12741 or a high-dose (100 to 200 milligrams) version of the ORM showed a 4 percent increase in scores. Scores were measured through a series of memory test administered online.
Still in the preliminary stages the drug seemed to show positive effects on cognitive memory. As for safety there was only 1 reported case of liver problems. All of the baseline monitors seemed to stay regular offering a very promising safety record. While showing promising effects their are many things to take into consideration. For one, these drugs were put on top of other drugs already treating the patients. While placed on top of other drugs seeing that we have seen promising increases in memory this means the drugs are working in cohesion with their medication to further prevent symptoms.
Although the drug is still in the preliminary stage and still has a lot of trails to go through before it can be a set medicine in the treatment of Alzheimer’s, it has already shown that it is a factor to be reckoned with. As stated by Rouru, the head researcher in this study, “I am afraid that wonder drugs hardly exist,” he noted. “In the present study, our drug was used on top of existing Alzheimer’s medications. In that setting it showed clear effect, which suggests that it is giving additional clinically significant benefit for patients that are already using Alzheimer’s
After writing my own summary of the research article I can see how hard it is to actually be a journalist. I now see the struggles that they have to go through to deliver a high quality piece of work that can be published and seen as an actual journal article instead of someone posting something online. I had difficulties putting my thoughts onto the paper in a way that the journalist did that really delivers the view of the researcher. I knew what I wanted to say about the research, but what I wanted to say didn’t really summarize the article or point out the key points that make the article. I also saw how difficult it really was to include every piece of information while having to shorten and summarize my article to a piece less than 2 pages. As far as the amount of stuff I could include into the article it wasn’t a matter of what to include or not to include it was how to do it and where to place it. I found myself leaving out some of the smaller details that referred to the study and mainly focusing on the main aspects that the study was going for such as the safety and the overall results. After this project and my multiple blog post I have a new fond respect for journalist. The amount of research they have to do into these studies and the amount of details they have to scrounge through to produce a perfect article is outstanding. I would compare my work to a little below what the original journal post was because my experience is not near what theirs was. I struggled with organization and going into detail in the short amount of space given. Overall I feel I covered what I needed to cover, but I feel as though I would’ve been able to do a lot better with more time and an extended work availability and word count.